Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2

Rafael Holdings

11/06/2026 12:44

Overview
U.S. biotechnology firm's fiscal Q3 revenue fell yr/yr, net loss narrowed
Company completed last patient visit in pivotal Phase 3 TransportNPC trial

Outlook
Company expects to submit NDA for Trappsol Cyclo in H2 2026
Company sees high unmet need in NPC market as a potential opportunity

Result Drivers
CYCLICAL THERAPEUTIC EXPENSES - Higher research and development costs driven by consolidation of Cyclo Therapeutic's expenses after March 2025 acquisition
LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell due to reduced payroll, stock-based compensation, and professional fees, partially offset by Cyclo expenses

Company press release: ID:nGNX9xMmYD

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
 
$179,000
 
Q3 EPS
 
-$0.08
 
Q3 Net Income Attributable To Co 
 
-$4.23 mln
 
Q3 Operating Income
 
-$6.87 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)